

FORM 7

MONTHLY PROGRESS REPORT

December 2016

Name of CSE Issuer	EVITRADE Health Systems Corp. (formerly, Auxellence Health Corporation), (the "Issuer")
Trading Symbol	EVA
Number of Issued Listed Securities	7,790,285
Number of Issued Outstanding Options	58,333
Number of Shares Reserved for Issuance	1,708,440 (from Warrants)
Number of Units Reserved for Issuance	1,400,000 (from Secured Credit Loan)
Number of Units Reserved for Issuance	1,103,575 (from Debt Settlement)
Date	January 5, 2017

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CSE Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the theCSE.com website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CSE Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer has effectively finalized all the details of the Plan of Arrangement from 2014 and is now awaiting confirmation from the companies that have been spun out to complete the share push outs as of the share record date.

The Issuer continues to communicate with a number of private venture capital firms, investment management, banks and brokerage firms for updates on the company for a possible financing.

The Issuer announced that its operator issued a Notice of Default and Demand for Payment for all amounts in arrears. The Issuer announced a private placement on February 22nd, 2016. On February 23rd, the Issuer announced that the Chairman arranged a \$1.05 Million secured convertible credit facility and that the financing was still open for expressions of interest until March 7th, 2016. On February 25th, 2016, the Issuer resolved the outstanding default issues and amounts with the operator in part by having the operator hold a debt with a convertibility feature of converting any amount of principle and/or interest at the terms of the current financing. The issuer closed a portion of the financing by issuing 1,300,000 units on March 16th, 2016. The issuer closed on a 2nd portion of the financing by issuing 2,000,000 units on April 7, 2017. The issuer announced an upgrade and release to its TULIP™ Health System in preparation of 2nd stage commercial pilot and marketing studies. In June the company announced the start of the Doctors Supervised Study (2nd stage of the Pilot trials) in addition to a sponsored research program with a major university for autonomous medical opportunities using the TULIP(TM) system. Management has been negotiating with various parties for possible sales and distribution arrangements with various parties and has signed a MOU with a Hong Kong marketing group for sales into China. Mr. York Lau was added as an advisor to the board in August 2016. Mr. C.K. Cheung was added as an advisor to the Board in the month of September 2016. The company underwent a re-branding and effected a name change to EVITRADE Health Systems Corp., a 15:1 share consolidation, and announced a minimum \$500K to a maximum \$1 million dollar private placement of which details were press released on October 3, 2016 for shares or convertible debt at \$2.50 per common share (no warrants were attached). The company provided an update on October 11th, that the Clinical studies were progressing satisfactory and site set-up was completed. Testing of the TULIP™ in Asia began October 13th and a purchase order for 500 systems was received by October 22nd for further testing. In addition, it was announced the advisor, Mr. C.K. Cheung was invited to join the board in October 2016 and was announced to become president of one of the company's subsidiary companies on November 11, 2016. The company announced the record date of November 15th, 2016 for the Annual General and Special Meeting to be held January 13, 2017 and the record date for shareholders to receive any share distributions for any dividend shares or for any divested subsidiary companies to be December 15, 2016. On November 16th, 2016 the issuer signed two MOUs: MOU#1 to acquire the "Voice of Heart" Electronic Healthcare Platform and MOU#2 to acquire hemp and cannabis assets, which includes a growing licence to grow cannabis on 50 hectares in Europe. Both transactions are pending satisfactory due diligence. On November 25th, 2016 the company announced the cancellation of the \$1 million financing at \$2.50 and the cancellation of 75,000 options to directors and to consultants to the company. The company has announced a change or adjournment of the Annual General and Special Meeting (AGSM) date to February 6, 2017, and a change of record date for the notice of meeting and record date for shareholders to vote at the AGSM to January 6, 2017.

Provide a general overview and discussion of the activities of management.

Management continues to pursue opportunities in the healthcare business. While the primary focus is still on customizing hardware technologies and software applications towards providing personalized health solutions for common health issues related to cardio-metabolic conditions, it is focussing initially on weight management. Management has been exposed to and presented with a number of health/medical opportunities, interesting software technologies, and other potential businesses. Management held an AGSM to approve the Plan of Arrangement and received final order from the Supreme Court of BC after shareholder approval was received. Management has completed the plan of arrangement and have spun out the subsidiaries from the Plan of Arrangement. The Company also continues to evaluate business opportunities in an endeavour to increase shareholder value. The primary business of the Issuer continues in the consumer health technology field and it is now working with various funding sources to ensure capital financing to continue to develop itself as an innovative consumer health solutions company. As the issuer has terminated the USA distribution agreement, it is focusing on its Canadian roll-out. Management continues with the usability testing of hardware and software components for marketing and commercial readiness purposes. The company has completed the initial commercial usability pilot for testing the system with both private and clinical users and has announced that has started the 2nd stage of the pilot. Management has retained counsel and consultants for listing on other international stock exchanges to increase visibility for the company and to potentially secure financing.

Management attended an OTC Markets event “OTCQX Vancouver Senior Executive and Issuer's Forum” featuring a panel discussion on cross-border capital raising opportunities for Canadian companies with various Canadian and American industry experts. Management continues with communications and discussions with various parties in the financing community and with numerous broker-dealers, private equity companies, investment fund companies, lawyers and venture capital companies for funding and for public / business relations and opportunities. Management has begun discussions with various parties for possible commercialization arrangements and has signed an MOU with a Hong Kong based marketing group for sales and distribution into China. Management has also been active in fulfilling administrative duties. Management has been involved in working with its operator for updating a new software release based on feedback from the initial Pioneer Pilot of the TULIP(TM) system and announced a new release on April 14, 2016 in preparation for the 2nd stage of the Pilot trials. In June, the company has announced the start of the Doctors Supervised Study (2nd stage of the Pilot trials) in addition to a sponsored research program with a major university for autonomous medical opportunities using the TULIP(TM) system. The company has signed an MOU for sales and distribution into China and added a strategic advisor to the board with expertise and connections in Asia. Management effected a name change, a share consolidation, added an additional advisor to the board and announced a private placement of up to \$1 million dollars at \$2.50. Management reported that the clinical site set-up was completed and the study was progressing satisfactory. Testing of the TULIP system in Asia began in October which resulted in a purchase order for 500 more systems for testing purposes. Advisor, C.K. Cheung was invited to join the board in October. Management was extremely busy in November completing all quarterly financial statements and reports for Q1 September 30, 2016 and filed it on SEDAR on November 29, 2016. In addition, management has begun conducting its due diligence on the two MOUs that have been announced. Management has been in discussion with at least two brokerage firms to conduct the due diligence on the industrial hemp and cannabis assets and to engage a brokerage firm to do a brokered financing for the industrial hemp business. Management has arranged contact with lawyers in Europe to assist with the due diligence of the industrial hemp business. Management reports that they have continued discussions with the Chinese group for sales and distribution into China and have been requested to assist in setting up three satellite offices in Hangzhou, Naning and Shanghai. At this time the Chinese marketing group continues to test the system. At a local level, management has been in discussions with a first nations elder to potentially locate a manufacturing facility on first nations land and to potentially scale manufacturing in Canada. Management is evaluating all options and determining what is economically feasible at the moment and will provide an update if there are any further developments in Asia or Canada from a marketing or manufacturing perspective. The clinical studies continue to progress satisfactorily if there is material or new to report, management will provide an update. Management arranged non-interest bearing loans to cover the monthly expenses. There are no other matters to report.

Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to report.

2. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report.

3. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The issuer signed an MOU#1 with Voice of Heart Integrated Healthcare Platform and MOU#2 for hemp and cannabis assets for its wholly owned subsidiary C&C Cosmeceuticals Corp. both announced on November 16th, 2016. Both transactions are subject to the completion of satisfactory due diligence and performance milestones.

4. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

The financing agreement between Intrinsic Venture Capital and the issuer had terms which had expired and was terminated as announced on June 5th, 2015. The company has been in discussions with Intrinsic Venture Capital to determine how to work with the company as announced on July 20, 2015. The financing agreement which was linked to the USA Distribution agreement had also been terminated as announced in the June 5th, 2015 corporate update portion of the press release. Previously a new USA licensing agreement on a non-exclusive basis has been offered and extended to the parties, subject to an upfront licensing and financing payment and approval by the intellectual property holder and creator, as announced on July 20, 2015. As there has been no further development on this front as no financing payment has been made this is no longer available and the issuer retains the opportunity to explore this option with any party. The previously mentioned possible Canadian rights for an ECG medical device has also not been financeable at this time and as a result there has been no further development and the agreement did not conclude.

Also, as previously announced and recapped in the December 23rd 2015 press release as posted on the CSE micro-website for the issuer and on SEDAR, the issuer has currently dissolved or terminated all agreements or engagements with the exception of continuing to work with the issuer's manufacturer, research and development operator.

The issuer terminated a consultant on November 1st, 2016 that was contracted for corporate finance development and business development.

On November 25th, 2016, the issuer cancelled the previously announced financing for \$1 million dollars at \$2.50 per share, and the cancellation of 75,000 options all priced below \$2.25.

5. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report.

6. Describe the acquisition of new customers or loss of customers.

None to report.

7. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to report.

8. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report.

9. Report on any labour disputes and resolutions of those disputes if applicable.

None to report.

10. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the

nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report.

11. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Issuer had approximately CDN\$1,161,399 plus USD\$24,950 in cash debt/loan advances owed to directors of the company.

The Issuer also had a total of \$74,851 of cash debt/loan advances from related party creditors.

The Issuer also has US\$10,000 of cash loans advanced from a related party creditor.

The Issuer also has US\$65,000 of cash loans advanced from a non-related parties

The Issuer has \$933,087.50 in cash debt loaned to the company by non-related parties.

12. Provide details of any securities issued and options or warrants granted in May 2016.

58,333 options granted in May 2016 priced from \$2.25 to \$3.00 (post consolidation currently remain outstanding after the November 25th, 2016 press release announcing the cancellation of 75,000 options)

500,000 shares were issued (subject to certain conditions and performance milestones and conditions) in conjunction with one of the MOU acquisitions signed.

13. Provide details of any loans to or by Related Persons.

Loans from directors, for CDN\$1,161,399 and USD\$24,950 of funds/loans to the company at of the date of this statement.

The Issuer also has \$74,851 of debt owed to related party creditors and approximately \$827,681 in convertible debt owed to the company's operator from the debt settlement.

The Issuer also has US\$10,000 of debt owed to a related party creditor.

14. Provide details of any changes in directors, officers or committee members.

Mr. C.K. Cheung to be appointed President of a subsidiary company.

15. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None to report.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer, which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: January 5, 2017.

Sydney Au
Name of Director or Senior Officer

"Sydney Au"
Signature
President and CEO
Official Capacity

Issuer Details Name of Issuer EVITRADE Health Systems Corp. (formerly, Auxellence Health Corporation)		For Month End December 2016	Date of Report January 5, 2017
Issuer Address c/o Mr. Faisal Manji, CFO / Sydney Au, CEO #168-11280 Twigg Place			
City/Province/Postal Code Richmond, BC, V6V 0A6	Issuer Fax No. N/A	Issuer Telephone No. (604) 780-3311	
Contact Name Sydney Au	Contact Position President & CEO	Contact Telephone No. (604) 780-3311	
Contact Email Address: ceo@auxellence.com	Web Site Address www.auxellence.com		